NYU Langone Heart Cardiologists Present Latest Clinical Findings and Research at ACC.2026
NEW YORK, March 28, 2026 /PRNewswire/ -- Cardiologists from NYU Langone Heart will present their latest clinical findings and research...
Read moreDetails
Press Releases – Lifestyle
Phase 3b data presented at AAD Annual Meeting show Lilly’s Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA...
Read moreDetailsUK Soft Gelatin Capsules Market to Reach USD 408.07 Million by 2032, Growing at a CAGR of 5.8% During 2026-2032 | MarkNtel Advisors
NEW DELHI, March 28, 2026 /PRNewswire/ -- According to the in-depth research report published by MarkNtel Advisors, the United Kingdom...
Read moreDetailsNorth America Water Pump Market Forecast to Reach USD 15 Billion by 2032, Reports MarkNtel Advisors
NEW DELHI, March 28, 2026 /PRNewswire/ -- According to the recent market study published by MarkNtel Advisors, the North America...
Read moreDetailsData from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis patientsRezpegaldesleukin proof-of-concept data...
Read moreDetails
PureHealth Research reports Why Targeted Supplements for Hearing Loss May Be Your Ears’ Best Defense
MANASSAS, Va., March 28, 2026 /PRNewswire/ -- PureHealth Research demonstrates auditory decline affects millions of adults – and for many,...
Read moreDetailsNuScale Power Corporation (SMR) Class Action Lawsuit: Investors Face March 13, 2026, Deadline
Did you buy SMR Class A common stock between May 13, 2025, and November 6, 2025?Affected NuScale Power Corporation Investor...
Read moreDetailsCHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in...
Read moreDetails
HELE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Helen of Troy
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Helen of Troy...
Read moreDetails
HTGC UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Hercules Capital (HTGC) Investors of Securities Class Action Deadline on May 19, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hercules Capital To Contact...
Read moreDetails